THE INVESTOR

메뉴열기

Medytox CEO to meet Allergan to discuss start of phase 3 trials of Innotox

PUBLISHED : July 11, 2017 - 17:20

UPDATED : July 12, 2017 - 11:40

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

[THE INVESTOR] Medytox CEO Jung Hyun-ho is slated to meet with executives at Allergan to discuss the start of phase 3 clinical trials of its liquid-type botulinum toxin Innotox this week, according to local news reports on July 11.

Medytox and Allergan struck a license partnership in 2013, when the Seoul-based company sold the global development and commercialization rights to Innotox to Allergan for US$360 million.




Jung’s recent visit to the US is aimed at cementing a concrete timetable for the US clinical trials of Innotox, according to local reports.

Allergan announced in its 2016 second quarter earnings report that it would begin the third-phase trials of Innotox in early 2017. However it is yet to begin the trials due to scale-up production issues with Medytox. Since then, Allergan had not publicized further plans for Innotox, fueling investor concerns.

A Medytox official told a local news outlet that the given production issues have been resolved and that it “expects Allergan to begin the phase 3 trials of Innotox by the end of this year.”

If Allergan does decide to carry out the final-stage trials of Innotox, the move is expected to lend a major revenue boost to Medytox which will produce and sell the liquid-injectable antiwrinkle fillers to be used in the trials to its global partner.

A Medytox spokesperson could not be reached for comment when contacted by The Korea Herald on July 11.

By Sohn Ji-young/The Korea Herald (jys@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
JUVENILE PROTECTION MANAGER : Shin Chang Hoon
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0615|Business info
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.